NR4A1 and metastatic neoplasm: Of 100 patients, 65 (65.0%) had hormone receptor-negative disease, 94 (94.0%) had metastatic disease, 66 (66.0%) had visceral metastases, and 21 (21.0%) had prior use of pertuzumab.